ACTU
Price
$4.73
Change
-$0.14 (-2.87%)
Updated
Feb 4, 02:17 PM (EDT)
Capitalization
112.38M
21 days until earnings call
Intraday BUY SELL Signals
DYN
Price
$18.14
Change
-$0.82 (-4.32%)
Updated
Feb 4, 02:38 PM (EDT)
Capitalization
3.12B
22 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACTU vs DYN

Header iconACTU vs DYN Comparison
Open Charts ACTU vs DYNBanner chart's image
Actuate Therapeutics
Price$4.73
Change-$0.14 (-2.87%)
Volume$100
Capitalization112.38M
Dyne Therapeutics
Price$18.14
Change-$0.82 (-4.32%)
Volume$300
Capitalization3.12B
ACTU vs DYN Comparison Chart in %
ACTU
Daily Signal:
Gain/Loss:
DYN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ACTU vs. DYN commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACTU is a Hold and DYN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ACTU: $4.87 vs. DYN: $18.96)
Brand notoriety: ACTU and DYN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACTU: 99% vs. DYN: 57%
Market capitalization -- ACTU: $112.38M vs. DYN: $3.12B
ACTU [@Biotechnology] is valued at $112.38M. DYN’s [@Biotechnology] market capitalization is $3.12B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACTU’s FA Score shows that 0 FA rating(s) are green whileDYN’s FA Score has 0 green FA rating(s).

  • ACTU’s FA Score: 0 green, 5 red.
  • DYN’s FA Score: 0 green, 5 red.
According to our system of comparison, DYN is a better buy in the long-term than ACTU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACTU’s TA Score shows that 4 TA indicator(s) are bullish while DYN’s TA Score has 3 bullish TA indicator(s).

  • ACTU’s TA Score: 4 bullish, 4 bearish.
  • DYN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ACTU is a better buy in the short-term than DYN.

Price Growth

ACTU (@Biotechnology) experienced а -10.64% price change this week, while DYN (@Biotechnology) price change was +5.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

ACTU is expected to report earnings on Feb 25, 2026.

DYN is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DYN($3.12B) has a higher market cap than ACTU($112M). DYN YTD gains are higher at: -3.067 vs. ACTU (-20.425). ACTU has higher annual earnings (EBITDA): -24.1M vs. DYN (-445.29M). DYN has more cash in the bank: 792M vs. ACTU (16.9M). ACTU (0) and DYN (0) have equivalent revenues.
ACTUDYNACTU / DYN
Capitalization112M3.12B4%
EBITDA-24.1M-445.29M5%
Gain YTD-20.425-3.067666%
P/E Ratio14.22N/A-
Revenue00-
Total Cash16.9M792M2%
Total DebtN/A120M-
TECHNICAL ANALYSIS
Technical Analysis
ACTUDYN
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 9 days ago
90%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 23 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ACTU
Daily Signal:
Gain/Loss:
DYN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BDNNY148.488.14
+5.80%
Boliden AB
PMMAF26.840.62
+2.36%
Puma AG Rudolf Dassler Sport
CDBMF0.62N/A
N/A
Cordoba Minerals Corp.
COLFF0.03N/A
N/A
Colabor Group Inc
HISJF13.09N/A
N/A
H I S Co., Ltd.

ACTU and

Correlation & Price change

A.I.dvisor tells us that ACTU and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACTU and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACTU
1D Price
Change %
ACTU100%
-3.18%
SYRE - ACTU
32%
Poorly correlated
+1.65%
DSGN - ACTU
28%
Poorly correlated
-0.38%
CLDX - ACTU
28%
Poorly correlated
+2.07%
DYN - ACTU
27%
Poorly correlated
+1.07%
NVAX - ACTU
27%
Poorly correlated
-3.68%
More

DYN and

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
+1.07%
RNA - DYN
63%
Loosely correlated
+0.26%
IDYA - DYN
57%
Loosely correlated
+0.50%
XNCR - DYN
53%
Loosely correlated
-0.99%
SYRE - DYN
53%
Loosely correlated
+1.65%
CRNX - DYN
53%
Loosely correlated
+1.24%
More